(1 - 18 from 19
)
FDA grants priority review to belzutifan for renal cell carcinoma subsetwww.healio.com › news › hematology-oncology › fda-grants-priority-revi...
www.healio.com
6 days ago · Objective response rate among patients with von Hippel-Lindau disease-associated renal cell carcinoma served as the primary endpoint. Results ...
sorted by relevance / date